k kumar  Yeni makale yazdı
2 w ·çevirmek

Mismatch Repair Deficiency Testing and Therapy: Market Outlook and Trends | #healthcare

Mismatch Repair Deficiency Testing and Therapy: Market Outlook and Trends

Mismatch Repair Deficiency Testing and Therapy: Market Outlook and Trends

Nivolumab's subsequent approval for metastatic colorectal cancer, particularly in combination with ipilimumab, validated dual checkpoint inhibition concepts and demonstrated enhanced therapeutic efficacy potential